Francis S E, Gluzman I Y, Oksman A, Knickerbocker A, Mueller R, Bryant M L, Sherman D R, Russell D G, Goldberg D E
Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO.
EMBO J. 1994 Jan 15;13(2):306-17. doi: 10.1002/j.1460-2075.1994.tb06263.x.
Intraerythrocytic malaria parasites rapidly degrade virtually all of the host cell hemoglobin. We have cloned the gene for an aspartic hemoglobinase that initiates the hemoglobin degradation pathway in Plasmodium falciparum. It encodes a protein with 35% homology to human renin and cathepsin D, but has an unusually long pro-piece that includes a putative membrane spanning anchor. Immunolocalization studies place the enzyme in the digestive vacuole and throughout the hemoglobin ingestion pathway, suggesting an unusual protein targeting route. A peptidomimetic inhibitor selectively blocks the aspartic hemoglobinase, prevents hemoglobin degradation and kills the organism. We conclude that Plasmodium hemoglobin catabolism is a prime target for antimalarial chemotherapy and have identified a lead compound towards this goal.
红细胞内的疟原虫能迅速降解几乎所有宿主细胞的血红蛋白。我们已克隆出一种天冬氨酸血红蛋白酶的基因,该酶启动了恶性疟原虫血红蛋白降解途径。它编码的蛋白质与人类肾素和组织蛋白酶D有35%的同源性,但有一个异常长的前肽,其中包括一个假定的跨膜锚定区。免疫定位研究表明该酶存在于消化泡以及整个血红蛋白摄取途径中,提示其蛋白质靶向途径不同寻常。一种拟肽抑制剂能选择性地阻断天冬氨酸血红蛋白酶,阻止血红蛋白降解并杀死疟原虫。我们得出结论,疟原虫血红蛋白分解代谢是抗疟化疗的主要靶点,并且已经确定了朝着这一目标的先导化合物。